Growth Factors and Biologics in Wound Care: 2026 Update

Growth Factors and Biologics in Wound Care

Growth factors and biologics represent the advanced end of the wound care therapeutic spectrum. When standard wound bed preparation — debridement, infection control, moisture balance, offloading — fails to produce measurable progress after 4 weeks of appropriate treatment, biologics offer mechanisms that the wound environment can no longer produce on its own. Understanding what these products do, what the evidence supports, and when payers will cover them is essential for wound care practitioners managing complex chronic wounds in 2026.

This article provides a clinician-focused overview of the major biologic categories, their evidence base, and practical considerations for integration into mobile wound care practice.

Platelet-Derived Growth Factor: The Original Biologic

Becaplermin (Regranex), a recombinant human platelet-derived growth factor (rhPDGF-BB), was the first FDA-approved growth factor for wound healing when it received clearance in 1997. It remains the only FDA-approved topical growth factor specifically indicated for diabetic foot ulcers.

Mechanism and Evidence

PDGF-BB promotes chemotaxis and proliferation of cells involved in wound repair, including fibroblasts, smooth muscle cells, and monocytes. The pivotal trial demonstrated a 50% complete healing rate in neuropathic diabetic foot ulcers versus 35% with placebo gel over 20 weeks.

Clinical considerations for PDGF use:

Indicated for lower extremity diabetic neuropathic ulcers extending into subcutaneous tissue or beyond
Requires adequate blood supply to the affected limb (not effective in ischemic wounds)
Applied as a thin layer once daily with a saline-moistened dressing
Must be used alongside sharp debridement — the wound bed must be clean
Treatment duration: typically 20 weeks or until complete healing

The FDA black box warning regarding malignancy risk in patients using three or more tubes should be discussed with patients and documented. Subsequent surveillance data has not confirmed a causal relationship, but the labeling persists and payers may reference it.

Platelet-Rich Plasma: Autologous Growth Factor Delivery

Platelet-rich plasma (PRP) concentrates the patient's own platelets to deliver supraphysiologic concentrations of multiple growth factors simultaneously — PDGF, TGF-beta, VEGF, EGF, and IGF-1 among others. The theoretical advantage over single growth factor therapy: wounds need multiple signals, not just one.

Preparation and Application

PRP is prepared by drawing the patient's blood (typically 30-60 mL), centrifuging it to concentrate platelets, and applying the resulting platelet concentrate directly to the wound bed. Some protocols activate the platelets with calcium chloride or thrombin before application; others apply the concentrate without activation.

Evidence Level

The evidence for PRP in wound healing is growing but heterogeneous. A 2024 Cochrane review found moderate-certainty evidence that PRP may increase healing of diabetic foot ulcers compared with standard care. However, the review noted significant variation in PRP preparation methods, concentration levels, and application protocols across studies, making it difficult to identify which specific PRP protocol is most effective.

Key practical considerations:

Requires point-of-care centrifuge equipment (cost: $3,000-$15,000 depending on system)
Processing adds 20-30 minutes to the visit
Medicare coverage varies by MAC jurisdiction — check your local coverage determination
Documentation must demonstrate failure of standard wound care for at least 4 weeks before initiating PRP
Contraindicated in patients with platelet disorders, active infection, or anticoagulation therapy (relative contraindication)

For billing considerations related to advanced wound therapies, see our skin substitute billing guide.

Amniotic Membrane Products: The Dominant Biologic Category

Amniotic membrane and placental tissue products have become the most widely used biologics in wound care. These products contain a matrix of collagen, growth factors, cytokines, and extracellular matrix proteins derived from donated human placental tissue. They provide both a scaffold for cell migration and a concentrated source of healing signals.

Product Categories

The amniotic membrane market includes several distinct product types:

Dehydrated human amnion/chorion membrane (dHACM) — Products like EpiFix and AmnioExCel. These are processed to preserve growth factors while removing cellular components. Applied directly to the wound bed after debridement.

Cryopreserved amniotic membrane — Products like Grafix. Cryopreservation retains viable cells in addition to the matrix and growth factors. Requires cold chain storage (-80C).

Amniotic fluid-derived products — Injectable or topical preparations derived from amniotic fluid rather than membrane tissue.

2026 Regulatory and Coverage Landscape

The CMS skin substitute billing changes that took effect in 2024-2025 reorganized how these products are categorized and reimbursed. Products are now classified based on their regulatory status:

PMA (Premarket Approval) products — full FDA review, highest evidence requirements
510(k) products — substantially equivalent to a predicate device
HCT/P (Section 361) products — regulated as human tissue, not as devices or drugs

This classification affects both coding (Q-codes vs. A-codes) and reimbursement rates. Practitioners should verify the current CMS classification and payment rate for any amniotic product before integrating it into their practice.

Clinical Application

Amniotic membrane products are typically applied after wound bed preparation:

Debride the wound to a clean, viable wound bed
Achieve hemostasis
Apply the product to cover the wound bed (some products require 1-2 cm overlap onto intact periwound skin)
Secure with a non-adherent secondary dressing
Reapply at intervals specified by the product protocol (weekly for most dHACM products)

For updated CPT and Q-code references, see our wound care CPT codes 2026 guide.

When to Consider Advanced Biologic Therapy

The decision to escalate from standard wound care to biologics should be systematic, not reflexive. Biologics are expensive, require documentation that justifies medical necessity, and are only effective when the underlying wound bed preparation is adequate.

Clinical Decision Criteria

Consider biologics when ALL of the following criteria are met:

The wound has been treated with appropriate standard care for at least 4 weeks
The wound has not demonstrated >40% reduction in surface area during that period
Underlying causes have been addressed (vascular status, glycemic control, nutrition, offloading)
The wound bed is clean (no necrotic tissue, no clinical infection)
Adequate blood supply is confirmed (ABI > 0.7 for lower extremity wounds)
The patient is adherent with the treatment plan

Documentation Requirements

Payers require documentation that demonstrates:

Duration and type of prior standard treatment
Objective wound measurements showing lack of progress
Confirmation that modifiable healing barriers have been addressed
Clinical rationale for the specific biologic selected
Planned treatment duration and reassessment intervals

Key Takeaways

Biologics should be considered after 4 weeks of appropriate standard wound care fails to produce measurable progress — they supplement wound bed preparation, they do not replace it
PRP provides autologous multi-growth-factor delivery but evidence remains heterogeneous and Medicare coverage varies by MAC jurisdiction
Amniotic membrane products are the most widely used wound care biologics — verify current CMS classification and reimbursement status before integrating any specific product
Documentation of prior standard care failure is the foundation of medical necessity for all biologic therapies — payers will deny claims that lack a documented 4-week treatment history
The 2026 regulatory landscape continues to evolve as CMS refines its skin substitute classification and payment framework